Molecular Imaging of Myocardial Fibrosis in Cardiac Amyloidosis
Status:
Not yet recruiting
Trial end date:
2024-06-30
Target enrollment:
Participant gender:
Summary
The primary aim of our pilot study is to determine whether fibrosis in the heart can be
measured with [68Ga]CBP8, a positron emission tomography (PET) probe, using PET/magnetic
resonance imaging (MRI) imaging, in 30 individuals with documented cardiac amyloidosis. We
will also enroll 15 individuals with recent myocardial infarction and 15 individuals with
hypertrophic cardiomyopathy as positive controls for fibrosis, and we will enroll 5
individuals without cardiovascular disease to undergo [68Ga]CBP8 PET/MRI imaging as a healthy
control group.
The primary hypothesis of this study is that [68Ga]CBP8 will bind to interstitial collagen
and quantify myocardial fibrosis in patients with cardiac amyloidosis. We hypothesize that
[68Ga]CBP8 uptake will be greater in patients with cardiac amyloidosis, myocardial fibrosis,
and hypertrophic cardiomyopathy than in healthy controls. Secondly, we also hypothesize that
[68Ga]CBP8 activity more strongly correlates with standard MRI measures in patients with
recent myocardial infarction and hypertrophic cardiomyopathy (where extracellular expansion
is caused by myocardial fibrosis/collagen deposition) than in patients with cardiac
amyloidosis (where myocardial fibrosis is combined with infiltration).